Exiqon Licenses miRNA Analysis Technology from Rosetta Inpharmatics

Nov 19, 2007

NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics.

The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.

Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.

Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu